Dr Pascal Gervaz

Chirurgien FMH, chirurgie interne & chirurgie viscérale



Comparison of Microsatellite Instability and Chromosomal Instability in Predicting Survival of Patients with T3N0 Colorectal Cancer




by Pascal Gervaz, MD, Jean-Philippe Cerottini, MD, Hanifa Bouzourene, MD, Dieter Hahnloser, MD, Christy L Doan, Jean Benhattar, MD, Pascal Chaubert, MD, Michelle Secic, MS, Michel Gillet, MD, John M Carethers, MD





At least 2 apparently independent mechanisms, microsatellite instability (MSI) and chromosomal instability, are implicated in colorectal tumorigenesis. Their respective roles in predicting clinical outcomes of patients with T3N0 colorectal cancer remain unknown.



Eighty-eight patients with a sporadic T3N0 colon or rectal adenocarcinoma were followed up for a median of 67 months. For chromosomal instability analysis, Ki-ras mutations were determined by single-strand polymerase chain reaction, and p53 protein staining was studied by immunohistochemistry. For MSI analysis, DNA was amplified by polymerase chain reaction at 7 microsatellite targets (BAT25, BAT26, D17S250, D2S123, D5S346, transforming growth factor receptor II, and BAX). Results. Overall 5-year survival rate was 72%. p53 protein nuclear staining was detected in 39 patients (44%), and MSI was detected in 21 patients (24%). MSI correlated with proximal location (P < .001) and mucinous content (P < .001). In a multivariate analysis, p53 protein expression carried a significant risk of death (relative risk = 4.0, 95% CI = 1.6 to 10.1, P = .004). By comparison, MSI was not a statistically significant prognostic factor for survival in this group (relative risk = 2.2, 95% CI = 0.6 to 7.3, P = .21).



p53 protein overexpression provides better prognostic discrimination than MSI in predicting survival of patients with T3N0 colorectal cancer. Although MSI is associated with specific clinicopathologic parameters, it did not predict overall survival in this group. Assessment of p53 protein expression by immunocytochemistry provides a simple means to identify a subset of T3N0 patients with a 4-times increased risk for death.

Back to top




in Surgery Volume 131, Issue 2, February 2002, Pages 190–197 - Pascal Gervaz, MD, Department of Colon & Rectal Surgery, Mayo Clinic, Mayo Building E-6A, 200 First St SW, Rochester, MN 55905